Hypothesis

Chronic mTOR inhibition with rapamycin during induced pluripotent stem cell (iPSC) reprogramming does not erase aging‑associated DNA methylation; instead it stabilizes a subset of age‑related CpG sites at bivalent promoters, producing iPSCs that retain an "epigenetic memory" of donor age despite expressing pluripotency markers.

Mechanistic Rationale

• Rapamycin inhibits mTORC1, reducing S6K‑mediated phosphorylation of DNMT1 [5]. This alteration shifts DNMT1 toward a more stable, maintenance‑mode activity rather than the dynamic turnover required for active demethylation during reprogramming.
• Concurrently, mTORC1 suppression lowers cellular ATP and acetyl‑CoA levels, limiting the substrate availability for TET enzymes that drive oxidation of 5‑mC to 5‑hmC and subsequent demethylation.
• The combined effect creates a metabolic milieu that favors preservation of methylation at CpG islands enriched for polycomb repressive complex 2 (PRC2) targets—regions known to acquire age‑related hypermethylation.
• Consequently, cells exit the reprogramming trajectory in a quasi‑naïve state: they express OCT4, SOX2, NANOG, but retain a methylation signature correlating with chronological age, akin to the "epigenetic drift slowing" observed in vivo [1,2].

Testable Predictions

1. Methylation age – iPSCs generated with rapamycin will show a higher Horvath or skin‑blood clock age than control iPSCs derived under identical conditions without the drug.
2. Targeted loci – Bisulfite sequencing will reveal significantly elevated methylation at a defined set of bivalent promoters (e.g., HOXA9, PDGFRA, FOXC1) in rapamycin‑treated iPSCs.
3. Functional consequence – These iPSCs will display delayed differentiation toward lineages governed by the hypermethylated promoters, yet retain comparable teratoma‑forming capacity, indicating a block in lineage priming rather than loss of pluripotency.
4. Rescue experiment – Transient overexpression of TET1 or supplementation with α‑ketoglutarate during the early reprogramming window will reduce the age‑associated methylation gap and restore timely differentiation kinetics.

Experimental Design

• Cell source: Human fibroblasts from donors aged 20, 40, and 60 years.
• Reprogramming: Send‑based OSKM expression with or without 10 nM rapamycin added from day 0 to day 14.
• Readouts:
  • Pluripotency marker flow cytometry (OCT4, SSEA‑4) at day 21.
  • Whole‑genome bisulfite sequencing (WGBS) to compute epigenetic age and map differentially methylated regions (DMRs).
  • RNA‑seq to assess lineage‑specific transcription factor expression during directed differentiation (e.g., neuroectoderm, mesoderm).
  • Differentiation efficiency quantified by marker‑positive cell percentages after 7‑day induction.
  • Teratoma formation in immunocompromised mice to confirm pluripotency.
• Controls: Vehicle (DMSO) treated parallel cultures; a second group receiving a dual mTORC1/C2 inhibitor (e.g., AZD8055) to test whether broader mTOR blockade exacerbates the phenotype.

Potential Implications

If validated, this hypothesis would reframe rapamycin’s role in reprogramming: rather than a neutral adjuvant, it acts as a metabolic brake that preserves epigenetic age information. This has two practical outcomes. First, it cautions against using rapamycin indiscriminately in protocols aimed at generating "young" iPSCs for disease modeling or autologous therapies, as the resulting cells may retain donor‑age methylation that could influence phenotype. Second, it suggests a combinatorial strategy—transient mTOR inhibition paired with targeted demethylation agents—to harness the autophagy‑ and anti‑inflammatory benefits of rapamycin while permitting a true epigenetic reset, thereby merging stress‑resistance with rejuvenation.

Falsifiability

The hypothesis is falsifiable if rapamycin‑treated iPSCs demonstrate epigenetic ages indistinguishable from controls and show no persistent methylation differences at the predicted bivalent promoters, or if their differentiation kinetics match or exceed those of rapamycin‑free iPSCs across all lineages.